An observational study in Cystic Fibrosis and Ventilatory Defect, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by University of North Carolina, Chapel Hill · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill — 2 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · University of North Carolina, Chapel Hill.
Among the 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill, this one is the only one that started in 2021, is one of 7 observational ones, and was the 20th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 1 mo–99 yrs
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 30 is below the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 16 across the 13 interventional studies, 152 across the 7 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also looks at how these measures change in response to a pulmonary exacerbation and treatment (if applicable). Over the span of a year, participants would be asked to complete 3-5 visits to the University of North Carolina at Chapel Hill (UNC). with each lasting up to 4 hours. If participants do not have a pulmonary exacerbation during the year they would be asked to complete 3 visits (one at enrollment, a second roughly 2 weeks later, and the third approximately a year later). If participants do experience a CF pulmonary exacerbation they would complete 5 visits (Visit 1, Visit 2, two exacerbation visits with one before treatment and the other after, and Visit 3 at one year after Visit 1). Only one exacerbation per participant will be tracked. Participants are eligible for this study if they are 18 years old or older, have Cystic Fibrosis (CF) with mild lung disease (FEV1 >/= 60%), and can undergo an MRI. There are no known benefits for participating in this study.
Adults with cystic fibrosis and stable lung disease at the time of enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the trial:
Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects to receive inhaled perfluoropropane via standard Douglas bag at every visit (3-5 visits). They will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant). Not to exceed 30 liters inhaled at each visit as this is the max capacity of our Douglas bag.
Combination Product: 19F MRI
Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
Also known as: Perfluoropropane (PFP)
Change in Ventilation Defect Parameter (VDP) over 14 days
VDP measured at Day 1 and Day 14, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 14
Change in VDP over 365 days
Average of VDP measured at Day 1 and Day 14; subtracted from VDP at Day 365, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 365 (+/- 30 days)
Change in FLVlongtau2 over 14 days
FLVlongtau2 measured at Day 1 and Day 14, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 14
Change in FLVlongtau2 over 365 days
Average of FLVlongtau2 measured at Day 1 and Day 14; subtracted from FLVlongtau2 at Day 365, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 365 (+/- 30 days)
Change in VDP occurring with a protocol-defined CF pulmonary exacerbation
Difference in VDP between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.
Time frame: Day 1 to Day 365 (+/- 30 days)
Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation
Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.
Time frame: Day 1 to Day 365 (+/- 30 days)
Change in MRI severity score over 365 days
Change in MRI severity score from baseline to Day 365.
Time frame: Day 1 to Day 365 (+/- 30 days)
Correlation of MRI severity score with VDP at baseline.
Baseline is a mean of the VDP scores from Day 1 and Day 14 (expressed as percentage of lung). Correlation of MRI scores with VDP and FLVlongtau2
Time frame: Day 1 to Day 14
Correlation of MRI severity score with FLVlongtau2 at baseline.
Baseline is a mean of the FLVlongtau2 scores from Day 1 and Day 14 (expressed as percentage of lung). Correlation of MRI scores with VDP and FLVlongtau2
Time frame: Day 1 to Day 14
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Aug 2026, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →